CZO Ceapro Inc.

Ceapro to Participate in the Virtual Investor Summer Spotlight Series

Ceapro to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Wednesday, July 12th at 1:00 PM ET

EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that of Ceapro and of the Angiogenesis Foundation will participate in the on Wednesday, July 12, 2023 at 1:00 PM ET.

A of the presentation will be available on the page of the section of the Company’s website (). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

For more information on Ceapro, please visit the Company’s website at .

For more information contact:

Jenene Thomas

JTC Team, LLC

Investor Relations and Corporate Communications Advisor

T (US): +1 (833) 475-8247

E:

Issuer:

Gilles R. Gagnon, M.Sc., MBA

President & CEO

T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release



EN
05/07/2023

Underlying

CZOCeapro Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ceapro Inc.

 PRESS RELEASE
Free
CZO CEAPRO INC.

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris and Ceapro Complete Merger Transaction TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce the successful completion and closing of their all-stock merger of equals transaction (the “Transaction”), which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023. “This is an important day for shareholders of ...

June 3, 2024 1 EN
 PRESS RELEASE
Free
CZO CEAPRO INC.

Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provi...

Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update – Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,000 in Q1 2023 – Announced approval by shareholders of merger of equals with Aeterna Zentaris to create a diversified biopharmaceutical company; expected to close in the second quarter of 2024, subject to the closing conditions EDMONTON, Alberta, ...

May 29, 2024 1 EN
 PRESS RELEASE
Free
CZO CEAPRO INC.

Ceapro Inc. Reports 2023 Financial Results and Operational Highlights

Ceapro Inc. Reports 2023 Financial Results and Operational Highlights – 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Sales impacted (decreased by 49% from $18.8M in 2022 to $9.6M in 2023) due to re-organization associated with the spin-off of the consumer division of one major customer – Announced merger of equals with Aeterna Zentaris ...

April 29, 2024 1 EN
 PRESS RELEASE
Free
CZO CEAPRO INC.

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate completing the Transaction i...

March 28, 2024 1 EN
 PRESS RELEASE
Free
CZO CEAPRO INC.

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Spec...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “Transaction”) at their respective special meetings held today. The specific voting results were as follows: Aeterna shareholders approved the Transaction with the following voting...

March 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch